Douglas M. Willis

Array ( [id] => 13879401 [patent_doc_number] => 20190036041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => Organometallic Iridium Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, Lighting Device, and Synthesis Method of Organometallic Iridium Complex [patent_app_type] => utility [patent_app_number] => 16/136590 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17922775 [patent_doc_number] => 11466008 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Co-crystals of neflamapimod (VX-745) [patent_app_type] => utility [patent_app_number] => 16/648267 [patent_app_country] => US [patent_app_date] => 2018-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 133 [patent_figures_cnt] => 241 [patent_no_of_words] => 21064 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 955 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17665287 [patent_doc_number] => 11358968 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Substituted epoxyeicosatrienoic acid (EET) analogs for treatment of kidney disease [patent_app_type] => utility [patent_app_number] => 16/647603 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4185 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14158647 [patent_doc_number] => 20190106426 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => IMIDAZOPYRAZINES AS LSD1 INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/130801 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16130801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17251109 [patent_doc_number] => 11186581 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-30 [patent_title] => 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-hydroxyphenyl)pyridazin-3-yl)acetamide as a Wnt pathway modulator [patent_app_type] => utility [patent_app_number] => 16/646655 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 7789 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15606159 [patent_doc_number] => 10584129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-10 [patent_title] => Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors [patent_app_type] => utility [patent_app_number] => 16/123009 [patent_app_country] => US [patent_app_date] => 2018-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 20 [patent_no_of_words] => 39360 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 215 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16123009 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15308931 [patent_doc_number] => 10519156 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-31 [patent_title] => 9'-Aza[3,9'-bi(bicyclo[3.3.1]nonan)]-3'-one and preparation thereof [patent_app_type] => utility [patent_app_number] => 16/120837 [patent_app_country] => US [patent_app_date] => 2018-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37762 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16120837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18369083 [patent_doc_number] => 11649237 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Substituted imidazo[1,5-a]pyrazines for IRE1 inhibition [patent_app_type] => utility [patent_app_number] => 16/642208 [patent_app_country] => US [patent_app_date] => 2018-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24136 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16642208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306297 [patent_doc_number] => 20190142852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE [patent_app_type] => utility [patent_app_number] => 16/118376 [patent_app_country] => US [patent_app_date] => 2018-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23899 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16118376 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581223 [patent_doc_number] => 20190218220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => HETEROARYL COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/114380 [patent_app_country] => US [patent_app_date] => 2018-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16114380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14697575 [patent_doc_number] => 10376509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-13 [patent_title] => Pharmaceutical compositions comprising clofazimine analog compound B746 or clofazimine analog compound B826 [patent_app_type] => utility [patent_app_number] => 16/108879 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 13626 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16108879 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15975453 [patent_doc_number] => 10668027 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-06-02 [patent_title] => Method of treating [patent_app_type] => utility [patent_app_number] => 15/999380 [patent_app_country] => US [patent_app_date] => 2018-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 18 [patent_no_of_words] => 17443 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15999380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17648470 [patent_doc_number] => 11351170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-07 [patent_title] => Substituted pyrimidines as CDK4/6 inhibitors [patent_app_type] => utility [patent_app_number] => 16/639412 [patent_app_country] => US [patent_app_date] => 2018-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42244 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 241 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111501 [patent_doc_number] => 20200207773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/639442 [patent_app_country] => US [patent_app_date] => 2018-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16639442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14087987 [patent_doc_number] => 10239885 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2019-03-26 [patent_title] => Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-a]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist [patent_app_type] => utility [patent_app_number] => 16/100315 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10729 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16283691 [patent_doc_number] => 20200277293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => POLYMORPHS OF SYK INHIBITORS [patent_app_type] => utility [patent_app_number] => 16/641331 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19987 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -64 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16641331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839412 [patent_doc_number] => 20210147424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => 1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/637298 [patent_app_country] => US [patent_app_date] => 2018-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24602 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17350860 [patent_doc_number] => 11225484 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-18 [patent_title] => Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4 [patent_app_type] => utility [patent_app_number] => 16/636887 [patent_app_country] => US [patent_app_date] => 2018-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17343 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621445 [patent_doc_number] => 20210040098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => APELIN RECEPTOR AGONISTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/637652 [patent_app_country] => US [patent_app_date] => 2018-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16637652 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17350851 [patent_doc_number] => 11225475 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-01-18 [patent_title] => Substituted pyridines as inhibitors of histone deacetylase [patent_app_type] => utility [patent_app_number] => 16/636969 [patent_app_country] => US [patent_app_date] => 2018-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10686 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16636969 [rel_patent_id] =>[rel_patent_doc_number] =>)